Developer docs
API playgroundTry for free, no card

Search company profiles

AAX Biotech

Full company profile

uuid0003c78

Namestring
AAX Biotech
Legal namestring
AAX Biotech AB
Websiteurl
aaxbiotech.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

AAX Biotech AB is a privately held Swedish biotech company spun out of Karolinska Institutet in 2022 (with research roots from 2020) and headquartered in Solna, Sweden. The company develops and commercializes two proprietary antibody engineering platforms: Seqitope®, a high-resolution, high-throughput epitope mapping technology based on massive parallel mutagenic scanning combined with next-generation sequencing (NGS), capable of characterizing up to 100 monoclonal antibody candidates in parallel; and Opti-mAb®, a molecular stabilization strategy for single-chain variable fragment (scFv) antibodies that improves expression yields and reduces aggregation for use in bispecific antibodies and CAR-T cell therapies. Both platforms are registered trademarks described as patentable and unique in their respective niches, particularly Opti-mAb which addresses a well-known instability problem in scFv formats with no widely applicable commercial alternative.

The company's business model combines fee-for-service research collaborations, technology licensing, and channel partnerships. Pricing is project-based and quote-driven, with no public rate cards; contracts tend toward multi-year engagements. Its customer base spans large pharmaceutical companies (Daiichi Sankyo, BioArctic), clinical-stage and early-stage biotechs (Vascurie, ToxoTech, Oblique Therapeutics), and academic groups (Karolinska Institutet Tran Research Group), with end applications in oncology, neurology, pain, and cardiovascular disease. Distribution occurs through direct enterprise sales led by the CEO and CBO, conference-based business development (BIO, PEGS, Antibody Engineering & Therapeutics), a Verified Supplier listing on Scientist.com, and a reseller agreement with evitria AG (part of Atlas Antibodies/Patricia Industries) for Opti-mAb research licenses.

The company operates with a small team of fewer than 10 employees. It has raised a 7 MSEK (~$682K) funding round in October 2024 led by Life Science Invest (LSI Epsilon), alongside existing investors Karolinska Institutet Holding, Northislet, Phase2Phase Biopharma Ventures, and HJKK Didrikson. A subsequent investment from Trio Impact Invest AB was announced in February 2026. Revenue figures are not publicly disclosed.

Short descriptiontext

AAX Biotech is a Swedish biotech spin-out from Karolinska Institutet that licenses Seqitope® (high-throughput epitope mapping) and Opti-mAb® (scFv stabilization) platforms to pharmaceutical and biotech companies developing antibody therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics platforms, epitope mapping services, scFv stabilization technology, antibody engineering services, biotherapeutics research services
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antibody Engineering Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Technology licensing and service contracts
TypeLicensing Royalties
Description

AAX Biotech generates revenue by licensing its proprietary Seqitope® and Opti-mAb® technologies to pharma and biotech companies, and by providing fee-for-service epitope mapping and antibody characterization projects. They execute collaborative research agreements with pharmaceutical partners (e.g., Daiichi Sankyo, Vascurie, ToxoTech, Oblique Therapeutics, BioArctic). Revenue is project-based and recurring as partnerships expand. The company also offers Opti-mAb® under research licenses through partners like evitria AG.

aaxbiotech.com
2Fee-for-service research collaborations
TypeProfessional Services
Description

AAX Biotech conducts paid research collaborations where partners pay for characterization services using the Seqitope® platform and robotic automation infrastructure. Projects include high-throughput antibody characterization (up to 100 antibodies in parallel). The company also serves as a Verified Supplier on Scientist.com, enabling direct service contracting with pharma and biotech buyers.

aaxbiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Project-based pricing for pharma and biotech companies
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is determined on a project-by-project basis through direct sales engagement. No public pricing tiers or rate cards are published. Access to services requires direct inquiry and contracting via the company's sales team or Scientist.com marketplace listing.

aaxbiotech.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AAX Biotech develops and licenses two proprietary antibody technology platforms — Seqitope® for high-resolution, high-throughput epitope mapping (up to 100 monoclonal antibodies analyzed in parallel with single amino acid resolution) and Opti-mAb® for stabilizing scFv antibodies used in bispecific antibodies and CAR-T therapies. The company delivers these platforms through technology licensing arrangements and fee-for-service antibody characterization research collaborations with pharmaceutical, biotech, and academic partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 100 antibodies characterized in parallel using Seqitope® platform with robotic automation infrastructure
+3 more records
Product overview1 text field

AAX Biotech operates as a dual-technology platform company offering two proprietary technology platforms for antibody therapeutics development. The core portfolio consists of Seqitope®, a high-resolution and high-throughput epitope mapping technology that processes up to 100 monoclonal antibodies in parallel, and Opti-mAb®, a novel scFv molecular stabilization technology that improves expression yields and reduces aggregation for next-generation antibody formats. Both technologies aim to accelerate drug development and improve therapeutic performance of antibody-based medicines including bispecific antibodies and CAR-T cell therapies.

Product and service2 records
1Seqitope®
CategoryAntibody epitope mapping platform
Description

Seqitope® is a high-resolution, high-throughput antibody epitope mapping platform based on massive parallel mutagenic scanning combined with next-generation sequencing. It processes up to 100 monoclonal antibody candidates in parallel at single amino acid resolution, accelerating antibody discovery, de-risking lead candidate selection, and supporting antibody affinity maturation. The platform is licensed to and used in fee-for-service research collaborations with pharmaceutical, biotech, and academic customers developing antibody therapeutics including bispecific antibodies, monoclonal antibodies, and CAR-T therapies.

2Opti-mAb®
CategoryAntibody engineering platform
Description

Opti-mAb® is a novel scFv molecular stabilization format that dramatically improves expression levels and reduces aggregation tendencies of single-chain variable fragment antibodies. It addresses the inherent instability problem of scFvs used in CAR-T cell therapies, bispecific antibodies, and other next-generation antibody therapeutics, improving production yields, reducing development costs, and enhancing pharmacological properties. The technology is licensed to pharmaceutical and biotech partners (including through channel partner evitria AG) and evaluated with collaborators such as Daiichi Sankyo.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Collaboration with Dr. Thuy Tran's research group at the Department of Oncology-Pathology, Karolinska Institutet. AAX Biotech applies Seqitope® to characterize novel anti-TROP2 antibodies developed by the Tran group and elucidate molecular features differentiating them from established TROP2 binders. TROP2 is a clinically validated cancer target with complex structure making characterization challenging.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-23
Description

Partnership with evitria AG, an expert provider of antibody engineering and expression services based in Zurich, Switzerland. evitria offers access to Opti-mAb® technology in early antibody development workflows, providing research licenses and incorporating the technology into multispecific antibody formats. evitria is part of the Atlas Antibodies group, a wholly-owned subsidiary of Patricia Industries.

Strategic tierMinorTypeOthersAnnounced on2026-01-29
Description

AAX Biotech was accepted into NOME, a Nordic mentor network providing tailored support from world-class mentors including Christine Richter, Magnus Björsne, Göran Forsberg, and Thorsten Thormann to strengthen commercial strategy and accelerate leadership in antibody-based medicine technologies.

4Vascurie
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Collaboration with neuro-oncology therapeutics developer Vascurie to advance high-throughput antibody characterization. AAX Biotech applies Seqitope® platform and robotic automation to characterize Vascurie's antibody candidates targeting CD93, a novel drug target. AAX Biotech can characterize up to 100 antibodies in parallel, providing rapid insights for Vascurie's neuro-oncology programs including lead candidate VDL-309. IND/CTA submission targeted for 2027 by Vascurie.

aaxbiotech.com
5ToxoTech
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Strategic collaboration to develop next-generation biotherapeutics for neurological disorders. The partnership combines AAX's Seqitope® platform with ToxoTech's expertise in biologic drug design to create novel biotherapeutic candidates with improved potency and precision. Seqitope® is applied to optimize receptor recognition and generate novel variants for neuromuscular and neurological indications.

aaxbiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-22
Description

Collaboration with global pharmaceutical leader Daiichi Sankyo (one of the global leaders in antibody-drug conjugates) to evaluate Opti-mAb® technology for next-generation antibody therapeutics. Conducted through Daiichi Sankyo's Munich research institute, the collaboration aims to explore broader applications of the platform to address medical needs. Represents significant validation of AAX Biotech's innovative approach.

7Confidential partner (clinical-stage cardiovascular program)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-07
Description

New collaboration focused on developing antibody-based therapies for acute and critical care of cardiovascular disease. AAX Biotech applies Seqitope® technology to conduct advanced epitope mapping of a humanized monoclonal antibody in clinical development, supporting regulatory submissions and optimizing clinical advancement.

aaxbiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-17
Description

BioArctic AB, a Swedish biopharma company focused on neurodegenerative diseases, decided to utilize AAX Biotech's proprietary Seqitope™ epitope mapping technology in a research project. This collaboration represents a significant milestone highlighting AAX Biotech's role in advancing neurodegenerative disease research.

9Oblique Therapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-28
Description

Strategic collaboration where AAX Biotech applies Seqitope™ technology to characterize antibody candidates of Oblique Therapeutics' pain program targeting TRPV1, providing invaluable insights for development. The collaboration represents the start of a broader and lasting collaboration on future drug candidates. Oblique Therapeutics noted that Seqitope® provided previously unattainable level of insight into drug candidate-target interactions.

aaxbiotech.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Oblique Therapeutics
TypeDirect peer
Description

Swedish biotech developing antibody therapeutics (TRPV1 pain program). AAX Biotech is an existing partner using Seqitope for their antibody candidates; both are Swedish antibody-focused biotechs of comparable scale.

TypeDirect peer
Description

Swedish biopharma focused on neurodegenerative diseases that has licensed Seqitope for antibody characterization. Comparable Swedish antibody/biologics peer serving similar therapeutic areas (neuro, oncology).

TypeDirect peer
Description

Swedish biotech platform company developing technology for membrane protein-based drug discovery (where CBO Maria Lisa Knudsen previously served as BD Director). Comparable Swedish biotech platform of similar scale.

TypeDirect peer
Description

Zurich-based antibody engineering and expression services provider (Atlas Antibodies/Patricia Industries subsidiary) that resells Opti-mAb research licenses. Directly comparable service provider in antibody engineering workflows.

TypeDirect peer
Description

Vancouver-based antibody discovery platform combining high-throughput screening, microfluidics, and AI to identify antibody candidates. Most directly comparable platform peer offering antibody discovery technology to pharma partners.

TypeDirect peer
Description

US-based antibody discovery and engineering platform offering yeast-based high-throughput antibody screening and optimization to pharma partners. Closely comparable business model and customer base to AAX Biotech.

TypeBroad incumbent
Description

Global biotech services company providing antibody discovery, synthesis, and characterization services at scale. Larger, broader player with overlapping capabilities in antibody R&D services that pharma buyers may compare AAX against.

TypeBroad incumbent
Description

Large life-sciences tools and reagents company with antibody-related products and services. Broader incumbent that competes for similar antibody-tooling budgets within pharma/biotech customers.

TypeBroad incumbent
Description

Global CRO offering extensive antibody discovery, characterization, and biologics manufacturing services. Larger incumbent serving the same enterprise pharma/biotech buyers with broader service portfolios.

TypeEmerging player
Description

US-based clinical-stage biotech developing bispecific and ADC antibody therapeutics. Relevant emerging peer as a potential customer for Opti-mAb scFv stabilization in bispecific workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AAX Biotech

Antibody Engineering Servicesaaxbiotech.com

AAX Biotech is a Swedish biotech spin-out from Karolinska Institutet that licenses Seqitope® (high-throughput epitope mapping) and Opti-mAb® (scFv stabilization) platforms to pharmaceutical and biotech companies developing antibody therapeutics.

What AAX Biotech does

AAX Biotech AB is a privately held Swedish biotech company spun out of Karolinska Institutet in 2022 (with research roots from 2020) and headquartered in Solna, Sweden. The company develops and commercializes two proprietary antibody engineering platforms: Seqitope®, a high-resolution, high-throughput epitope mapping technology based on massive parallel mutagenic scanning combined with next-generation sequencing (NGS), capable of characterizing up to 100 monoclonal antibody candidates in parallel; and Opti-mAb®, a molecular stabilization strategy for single-chain variable fragment (scFv) antibodies that improves expression yields and reduces aggregation for use in bispecific antibodies and CAR-T cell therapies. Both platforms are registered trademarks described as patentable and unique in their respective niches, particularly Opti-mAb which addresses a well-known instability problem in scFv formats with no widely applicable commercial alternative.

The company's business model combines fee-for-service research collaborations, technology licensing, and channel partnerships. Pricing is project-based and quote-driven, with no public rate cards; contracts tend toward multi-year engagements. Its customer base spans large pharmaceutical companies (Daiichi Sankyo, BioArctic), clinical-stage and early-stage biotechs (Vascurie, ToxoTech, Oblique Therapeutics), and academic groups (Karolinska Institutet Tran Research Group), with end applications in oncology, neurology, pain, and cardiovascular disease. Distribution occurs through direct enterprise sales led by the CEO and CBO, conference-based business development (BIO, PEGS, Antibody Engineering & Therapeutics), a Verified Supplier listing on Scientist.com, and a reseller agreement with evitria AG (part of Atlas Antibodies/Patricia Industries) for Opti-mAb research licenses.

The company operates with a small team of fewer than 10 employees. It has raised a 7 MSEK (~$682K) funding round in October 2024 led by Life Science Invest (LSI Epsilon), alongside existing investors Karolinska Institutet Holding, Northislet, Phase2Phase Biopharma Ventures, and HJKK Didrikson. A subsequent investment from Trio Impact Invest AB was announced in February 2026. Revenue figures are not publicly disclosed.

AAX Biotech firmographics

Firmographics
Name
AAX Biotech
Legal name
AAX Biotech AB
Website
https://aaxbiotech.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
AAX Biotech is a Swedish biotech spin-out from Karolinska Institutet that licenses Seqitope® (high-throughput epitope mapping) and Opti-mAb® (scFv stabilization) platforms to pharmaceutical and biotech companies developing antibody therapeutics.
Ownership category
akta.pro rank

AAX Biotech industry classification

Industry
Product category
Antibody Engineering Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody therapeutics platforms
  • Epitope mapping services
  • ScFv stabilization technology
  • Antibody engineering services
  • Biotherapeutics research services

Where AAX Biotech is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

AAX Biotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology licensing and service contracts: AAX Biotech generates revenue by licensing its proprietary Seqitope® and Opti-mAb® technologies to pharma and biotech companies, and by providing fee-for-service epitope mapping and antibody characterization projects. They execute collaborative research agreements with pharmaceutical partners (e.g., Daiichi Sankyo, Vascurie, ToxoTech, Oblique Therapeutics, BioArctic). Revenue is project-based and recurring as partnerships expand. The company also offers Opti-mAb® under research licenses through partners like evitria AG.
  2. Fee-for-service research collaborations: AAX Biotech conducts paid research collaborations where partners pay for characterization services using the Seqitope® platform and robotic automation infrastructure. Projects include high-throughput antibody characterization (up to 100 antibodies in parallel). The company also serves as a Verified Supplier on Scientist.com, enabling direct service contracting with pharma and biotech buyers.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based pricing for pharma and biotech companies

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

AAX Biotech product offering

Product offering

Core offering

AAX Biotech develops and licenses two proprietary antibody technology platforms — Seqitope® for high-resolution, high-throughput epitope mapping (up to 100 monoclonal antibodies analyzed in parallel with single amino acid resolution) and Opti-mAb® for stabilizing scFv antibodies used in bispecific antibodies and CAR-T therapies. The company delivers these platforms through technology licensing arrangements and fee-for-service antibody characterization research collaborations with pharmaceutical, biotech, and academic partners.

Product overview

AAX Biotech operates as a dual-technology platform company offering two proprietary technology platforms for antibody therapeutics development. The core portfolio consists of Seqitope®, a high-resolution and high-throughput epitope mapping technology that processes up to 100 monoclonal antibodies in parallel, and Opti-mAb®, a novel scFv molecular stabilization technology that improves expression yields and reduces aggregation for next-generation antibody formats. Both technologies aim to accelerate drug development and improve therapeutic performance of antibody-based medicines including bispecific antibodies and CAR-T cell therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Seqitope® Seqitope® is a high-resolution, high-throughput antibody epitope mapping platform based on massive parallel mutagenic scanning combined with next-generation sequencing. It processes up to 100 monoclonal antibody candidates in parallel at single amino acid resolution, accelerating antibody discovery, de-risking lead candidate selection, and supporting antibody affinity maturation. The platform is licensed to and used in fee-for-service research collaborations with pharmaceutical, biotech, and academic customers developing antibody therapeutics including bispecific antibodies, monoclonal antibodies, and CAR-T therapies.
  • Opti-mAb® Opti-mAb® is a novel scFv molecular stabilization format that dramatically improves expression levels and reduces aggregation tendencies of single-chain variable fragment antibodies. It addresses the inherent instability problem of scFvs used in CAR-T cell therapies, bispecific antibodies, and other next-generation antibody therapeutics, improving production yields, reducing development costs, and enhancing pharmacological properties. The technology is licensed to pharmaceutical and biotech partners (including through channel partner evitria AG) and evaluated with collaborators such as Daiichi Sankyo.

Quantifiable outcome

  • Up to 100 antibodies characterized in parallel using Seqitope® platform with robotic automation infrastructure
  • +3 more outcomes

Companies that use AAX Biotech

Customer profile

Named customers7 records

Segments2 records

Ideal customer profiles2 records

AAX Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature2 records

AAX Biotech partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Karolinska Institutet (Tran Research Group)coreStrategic or Co-development Partner · 2 June 2026Collaboration with Dr. Thuy Tran's research group at the Department of Oncology-Pathology, Karolinska Institutet. AAX Biotech applies Seqitope® to characterize novel anti-TROP2 antibodies developed by the Tran group and elucidate molecular features differentiating them from established TROP2 binders. TROP2 is a clinically validated cancer target with complex structure making characterization challenging.
  • evitria AGcoreChannel Partner/ Reseller/ Distributor · 23 April 2026Partnership with evitria AG, an expert provider of antibody engineering and expression services based in Zurich, Switzerland. evitria offers access to Opti-mAb® technology in early antibody development workflows, providing research licenses and incorporating the technology into multispecific antibody formats. evitria is part of the Atlas Antibodies group, a wholly-owned subsidiary of Patricia Industries.
  • Nordic Mentor Network for Entrepreneurship (NOME)minorOthers · 29 January 2026AAX Biotech was accepted into NOME, a Nordic mentor network providing tailored support from world-class mentors including Christine Richter, Magnus Björsne, Göran Forsberg, and Thorsten Thormann to strengthen commercial strategy and accelerate leadership in antibody-based medicine technologies.
  • VascuriecoreStrategic or Co-development Partner · 20 January 2026Collaboration with neuro-oncology therapeutics developer Vascurie to advance high-throughput antibody characterization. AAX Biotech applies Seqitope® platform and robotic automation to characterize Vascurie's antibody candidates targeting CD93, a novel drug target. AAX Biotech can characterize up to 100 antibodies in parallel, providing rapid insights for Vascurie's neuro-oncology programs including lead candidate VDL-309. IND/CTA submission targeted for 2027 by Vascurie.
  • ToxoTechcoreStrategic or Co-development Partner · 6 November 2025Strategic collaboration to develop next-generation biotherapeutics for neurological disorders. The partnership combines AAX's Seqitope® platform with ToxoTech's expertise in biologic drug design to create novel biotherapeutic candidates with improved potency and precision. Seqitope® is applied to optimize receptor recognition and generate novel variants for neuromuscular and neurological indications.
  • Daiichi SankyocoreStrategic or Co-development Partner · 22 October 2025Collaboration with global pharmaceutical leader Daiichi Sankyo (one of the global leaders in antibody-drug conjugates) to evaluate Opti-mAb® technology for next-generation antibody therapeutics. Conducted through Daiichi Sankyo's Munich research institute, the collaboration aims to explore broader applications of the platform to address medical needs. Represents significant validation of AAX Biotech's innovative approach.
  • Confidential partner (clinical-stage cardiovascular program)coreStrategic or Co-development Partner · 7 May 2025New collaboration focused on developing antibody-based therapies for acute and critical care of cardiovascular disease. AAX Biotech applies Seqitope® technology to conduct advanced epitope mapping of a humanized monoclonal antibody in clinical development, supporting regulatory submissions and optimizing clinical advancement.
  • BioArcticcoreStrategic or Co-development Partner · 17 April 2024BioArctic AB, a Swedish biopharma company focused on neurodegenerative diseases, decided to utilize AAX Biotech's proprietary Seqitope™ epitope mapping technology in a research project. This collaboration represents a significant milestone highlighting AAX Biotech's role in advancing neurodegenerative disease research.
  • Oblique TherapeuticscoreStrategic or Co-development Partner · 28 November 2023Strategic collaboration where AAX Biotech applies Seqitope™ technology to characterize antibody candidates of Oblique Therapeutics' pain program targeting TRPV1, providing invaluable insights for development. The collaboration represents the start of a broader and lasting collaboration on future drug candidates. Oblique Therapeutics noted that Seqitope® provided previously unattainable level of insight into drug candidate-target interactions.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

AAX Biotech competitors and assessment

Company assessment

Direct peers

  • Oblique Therapeutics: Swedish biotech developing antibody therapeutics (TRPV1 pain program). AAX Biotech is an existing partner using Seqitope for their antibody candidates; both are Swedish antibody-focused biotechs of comparable scale.
  • BioArctic: Swedish biopharma focused on neurodegenerative diseases that has licensed Seqitope for antibody characterization. Comparable Swedish antibody/biologics peer serving similar therapeutic areas (neuro, oncology).
  • Salipro Biotech: Swedish biotech platform company developing technology for membrane protein-based drug discovery (where CBO Maria Lisa Knudsen previously served as BD Director). Comparable Swedish biotech platform of similar scale.
  • evitria AG: Zurich-based antibody engineering and expression services provider (Atlas Antibodies/Patricia Industries subsidiary) that resells Opti-mAb research licenses. Directly comparable service provider in antibody engineering workflows.
  • AbCellera Biologics: Vancouver-based antibody discovery platform combining high-throughput screening, microfluidics, and AI to identify antibody candidates. Most directly comparable platform peer offering antibody discovery technology to pharma partners.
  • Adimab: US-based antibody discovery and engineering platform offering yeast-based high-throughput antibody screening and optimization to pharma partners. Closely comparable business model and customer base to AAX Biotech.

Broad incumbents

  • GenScript: Global biotech services company providing antibody discovery, synthesis, and characterization services at scale. Larger, broader player with overlapping capabilities in antibody R&D services that pharma buyers may compare AAX against.
  • Bio-Techne: Large life-sciences tools and reagents company with antibody-related products and services. Broader incumbent that competes for similar antibody-tooling budgets within pharma/biotech customers.
  • Charles River Laboratories: Global CRO offering extensive antibody discovery, characterization, and biologics manufacturing services. Larger incumbent serving the same enterprise pharma/biotech buyers with broader service portfolios.

Emerging players

  • SystImmune: US-based clinical-stage biotech developing bispecific and ADC antibody therapeutics. Relevant emerging peer as a potential customer for Opti-mAb scFv stabilization in bispecific workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

AAX Biotech social profiles

Digital presence

AAX Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AAX Biotech leadership team

Management profile

Number of profiles

Profiles12 records

AAX Biotech funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AAX Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AAX Biotech

What does AAX Biotech do?

AAX Biotech develops and licenses two proprietary antibody technology platforms — Seqitope® for high-resolution, high-throughput epitope mapping (up to 100 monoclonal antibodies analyzed in parallel with single amino acid resolution) and Opti-mAb® for stabilizing scFv antibodies used in bispecific antibodies and CAR-T therapies. The company delivers these platforms through technology licensing arrangements and fee-for-service antibody characterization research collaborations with pharmaceutical, biotech, and academic partners.

Is AAX Biotech a public or private company?

AAX Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was AAX Biotech founded?

AAX Biotech was founded in 2022. It employs 11 to 50 people.

Where is AAX Biotech based?

AAX Biotech is headquartered in Stockholm, Sweden, in the Europe region.

How does AAX Biotech make money?

Two revenue lines are on record. Technology licensing and service contracts are the primary driver. The others are fee-for-service research collaborations.

Who are AAX Biotech's main competitors?

Direct peers on record are Oblique Therapeutics, BioArctic, Salipro Biotech, evitria AG, AbCellera Biologics and Adimab. Broad incumbents are GenScript, Bio-Techne and Charles River Laboratories. SystImmune is listed as an emerging player.

Does AAX Biotech have an API?

No public API is recorded for AAX Biotech.

What industry is AAX Biotech in?

AAX Biotech's product category is Antibody Engineering Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comAAX Biotech and Discovery Evolution collaborate to develop bispecific antibodies for oncologyAAX Biotech and Discovery Evolution announced a research collaboration to develop bispecific antibody candidates for oncology, combining AAX's Opti-mAb technology with Discovery Evolution's RedQueen digital antibody discovery. The partnership aims to generate differentiated therapeutic candidates for preclinical evaluation, with no therapeutic efficacy or safety established.The Pharma LetterAAX Biotech appoints new CEO as it targets commercial growthAAX Biotech appointed Sarah Fredriksson as CEO on November 1, aiming to convert interest in its antibody technologies into commercial partnerships. Co-founder Daniel X Johansson will remain chief scientific officer and board member.Business & FinancialAAX Biotech appoints Sarah Fredriksson as CEOAAX Biotech appointed Sarah Fredriksson as CEO effective 1 November 2026, with Daniel X Johansson remaining as CSO. The appointment marks a transition from technology validation to commercial scale-up, with platforms selected by Daiichi Sankyo and offered via partner Evitria. The next priority is converting momentum into partnerships and licensing agreements.news.cision.comAAX Biotech appoints Sarah Fredriksson as CEOAAX Biotech appointed Sarah Fredriksson as CEO, effective 1 November 2026, bringing over 20 years of life sciences leadership. The appointment marks the company's transition from technology validation to commercial scale-up, with proprietary platforms selected by global pharma. The next priority is converting momentum into partnerships and licensing agreements.NotifiedAAX Biotech Wins Pitch Competition, Glue4Life takes home Innovation Poster Exhibition at NLSdaysAAX Biotech won the Nordic Star Pitch Competition at NLSDays 2026, receiving a 10,000 EUR prize and two tickets to next year's event. Glue4Life took the Innovation Poster Exhibition prize for its hydrogel platform. The Stockholm event featured 14 pitch competitors and 22 poster exhibitors.NotifiedAAX Biotech Wins Pitch Competition, Glue4Life takes home Innovation Poster Exhibition at NLSdaysAAX Biotech won the Nordic Star Pitch Competition at NLSDays 2026, receiving a 10,000 EUR cash prize and two tickets to next year's event. Glue4Life took home the Innovation Poster Exhibition prize for its hydrogel platform. The awards were presented at the Stockholm conference.news.cision.comAAX Biotech Enters Next Phase of Collaboration with Daiichi Sankyo Following Initial Evaluation of Opti-mAb® TechnologyAAX Biotech and Daiichi Sankyo advanced their collaboration into an antibody program after an initial evaluation of AAX's Opti-mAb technology. The research-stage partnership, announced in October 2025, will continue exploring the technology's potential in next-generation antibody therapeutics. No conclusions have been reached on future development or commercialization.news.cision.comAAX Biotech and evitria to expand access to Opti-mAb® technology in early antibody developmentAAX Biotech and evitria announced a partnership to give evitria customers access to AAX's Opti-mAb technology for early antibody development. The technology improves stability of single-chain variable fragments, and evitria may incorporate it into multispecific formats. The partnership aims to expand Opti-mAb use across antibody discovery programs.news.cision.comAAX Biotech secures investment from Trio Impact InvestSwedish biotech company AAX Biotech has secured an investment from Trio Impact Invest, a Swedish deep tech venture capital firm, to support the development and scaling of its proprietary antibody technology platforms including Seqitope® and Opti-m-Ab®. The investment, Trio Impact Invest's first from its fund, will be allocated toward platform advancement and expanding industry partnerships, including an existing collaboration with Daiichi Sankyo. The funding marks the next phase of growth for AAX Biotech as it seeks to broaden the impact of its antibody discovery and optimization technologies.AaxbiotechAAX Biotech secures investment from Trio Impact Invest — AAX BIOTECHSwedish venture capital firm Trio Impact Invest AB has invested in AAX Biotech, a biotech company specializing in antibody-based medicines, to support the development and scaling of its proprietary technology platforms Seqitope® and Opti-mAb®. The investment will fund platform advancement and the continued development of industry partnerships, following a period of technological and commercial progress including advanced automation implementation and new collaborations with pharmaceutical companies. The funding enables AAX Biotech to broaden the impact of its antibody discovery and optimization technologies and strengthen collaborations with both new and existing partners.